Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...
A team of Australian researchers has developed a new targeted therapeutic approach that could improve treatment for myelofibrosis -- a rare and serious form of blood cancer. Myelofibrosis disrupts the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results